<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647672</url>
  </required_header>
  <id_info>
    <org_study_id>aesa</org_study_id>
    <nct_id>NCT01647672</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
  <official_title>A Study to Assess the Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in the Treatment of Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Select 60 cases of women with breast cancer at clinical stage of T1-4N0-2M0. Then treat them
      with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500 mg/m2, 21day/cycle) as
      neoadjuvant chemotherapy. Finally the investigators assess the efficacy and safety of
      Albumin-bound Paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators select 60 cases of women with breast cancer at clinical stage of
      T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500
      mg/m2, 21day/cycle) as neoadjuvant chemotherapy. Finally the investigators assess the
      efficacy and safety of Albumin-bound Paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapeutic assessment</measure>
    <time_frame>6 months</time_frame>
    <description>therapeutic assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions and disease-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Adverse reactions during the treatment and disease-free survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence or death</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence or death</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Abraxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abraxane for neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Abraxane for neoadjuvant chemotherapy</description>
    <arm_group_label>Abraxane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Karnofsky ≥ 70

          2. Provision of informed consent

          3. Pathological confirmation of breast cancer

          4. Tumor stage (TNM):T2-4bN0-3M0

          5. Measurable disease as per RECIST criteria

          6. Not previously treated with radiotherapy, chemotherapy or biological therapy.

          7. Laboratory criteria:

               -  PLT ≥ 100*109/L

               -  WBC ≥ 4000/mm3

               -  HGB ≥ 10g/dl

               -  GOT,GPT,ALP ≤ 2*ULN

               -  TBIL,DBIL,CCr ≤ 1.5*ULN

        Exclusion Criteria:

          1. Pregnant woman

          2. History of organ transplantation

          3. With mental disease

          4. With severe infection or active gastrointestinal ulcers

          5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or
             diabetes

          6. Disease-free period of other malignant tumor is less than 5 years (except cured basal
             cell skin cancer and cervical carcinoma in situ)

          7. With heart disease

          8. Experimental drug allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Zhang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Cancer hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHANG SHENG, DOCTOR</last_name>
      <phone>86-022-23340123</phone>
      <phone_ext>2901</phone_ext>
    </contact>
    <contact_backup>
      <last_name>ZHANG SHENG, DORTOR</last_name>
      <phone>86-022-23340123</phone>
      <phone_ext>2901</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>ZHANG JIN, PROFESSOR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2012</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University</investigator_affiliation>
    <investigator_full_name>Zhang jin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

